Objective: Despite the high worldwide prevalence of asthma and headache, little is known about the association between these conditions. The objective of our study was to evaluate the association between asthma and daily headache in a representative sample of the general population of South Korea.
Methods: We retrospectively analyzed 7984 individuals included in the Second Korean National Health and Nutrition Examination Survey (KNHANES II), a prospectively administered survey performed in 2001 by a government organization within the Ministry of Health and Welfare. After adjustment of risk factors for daily headache, multivariate logistic regression analysis was performed to evaluate the association between asthma and daily headache.
Results: Of 7984 individuals, 69 (0.9%) had daily headache and 429 (5.4%) had asthma symptoms. Daily headache was significantly more prevalent in subjects with asthma symptoms (14/429, 3.3%) than in those without (55/7555, 0.7%; p < 0.001). Of the 4833 nonsmokers, 46 (1.0%) had daily headache and 287 (5.9%) had asthma symptoms, with daily headache being significantly more prevalent in subjects with asthma symptoms (11/231, 4.8%) than in those without (35/4602, 0.8%; p < 0.001). Multivariate logistic regression showed that the odds ratios for daily headache were 2.3 (95% CI: 1.21-4.33, p = 0.01) in all individuals with asthma symptoms and 3.4 (95% CI: 1.65-7.12, p = 0.001) in nonsmokers with asthma symptoms.
Conclusion: Individuals with asthma symptoms are at higher risk of daily headache than those without the symptoms, suggesting a link between these conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/02770903.2013.795587 | DOI Listing |
Am J Emerg Med
January 2025
Department of Emergency Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, United States of America. Electronic address:
Bacterial meningitis is an increasingly rare disease that carries significant morbidity and mortality. We describe the case of a 38-year-old male with a past medical history of pituitary macroadenoma with prior endonasal surgeries on prednisone therapy daily for resultant hypopituitarism and juvenile myoclonic epilepsy on lamotrigine daily who was transferred to an academic tertiary emergency department due to concern for developing pituitary apoplexy. At the outside emergency department, the patient presented complaining of sudden onset severe headache.
View Article and Find Full Text PDFLancet Neurol
February 2025
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.
View Article and Find Full Text PDFLancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFJ Clin Med
January 2025
Disturbances of Growth and Development on Children Research Center, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is increasingly recognized as a condition affecting not only adults but also children and adolescents. While children often experience milder acute COVID-19 symptoms compared to adults, some develop persistent physical, psychological, and neurological symptoms lasting for weeks or months after initial infection. The most commonly reported symptoms include debilitating fatigue, respiratory issues, headaches, muscle pain, gastrointestinal disturbances, and cognitive difficulties, which significantly impact daily activities, schooling, and social interactions.
View Article and Find Full Text PDFCrit Care Explor
January 2025
Department of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive Care, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.
Objectives: The COVID-19 pandemic gave rise to uncertainty concerning potential sequelae related to a severe acute respiratory syndrome coronavirus 2 infection. This landscape is currently unfolding with studies reporting sequelae on various domains (physical, cognitive, and psychosocial), although most studies focus on adults or only one domain. We sought to investigate concurrent sequelae on multiple domains 1 year after PICU admission for Multisystem Inflammatory Syndrome in Children (MIS-C).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!